Cytek Q2 revenue $40.2M (+32% YoY); net loss of $0.7M vs prior-year net income $2.7M

Cytek Biosciences, Inc.

2022-Q2 EPS reported -$0.02 revenue$75,223,000

Revenue $40.2M, up 32% YoY; gross profit $24.6M (61% margin) vs $19.7M (65% margin) prior year.
Operating loss $0.9M vs operating income $3.8M in Q2 2021; net loss $0.7M vs prior net income $2.7M.
Adjusted EBITDA $4.8M flat YoY; installed base 1,356 instruments (130 placed in quarter).
Full-year 2022 revenue guidance reaffirmed: closer to high end of $160M-$168M range.
Received CE mark for cFluor reagents and TBNK kit for European clinical market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.